查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2084941

自體免疫疾病診斷市場：2026-2032年全球市場預測（依產品類型、檢測類型、技術、檢體類型、適應症、最終用戶和通路分類）

Autoimmune Disease Diagnostics Market by Product, Test Type, Technology, Sample Type, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，自體免疫疾病診斷市場將成長至 103 億美元，複合年成長率為 7.45%。

主要市場統計數據
基準年 2025 62.3億美元
預計年份：2026年 66.8億美元
預測年份 2032 103億美元
複合年成長率 (%) 7.45%

自體免疫疾病的診斷正從間歇性的、基於症狀的檢測轉向更早、基於多種標誌物的縱向評估，這一趨勢已蔓延至風濕病學、胃腸病學、內分泌學、神經病學、腎臟病學和皮膚病學等領域。這種轉變的促進因素包括自體免疫疾病帶來的沉重臨床負擔、全身性紅斑性狼瘡、類風濕性關節炎、自體免疫甲狀腺疾病、1型糖尿病、發炎性腸道疾病和乳糜瀉等疾病的診斷延遲，以及需要區分發炎性、感染性、惡性和遺傳性等相似疾病。

該市場由成熟的技術支撐，例如間接螢光、化學冷光免疫檢測（ELISA）、化學發光免疫分析法、補體檢測、 HLA型檢測、組織轉谷氨醯胺酶檢測、抗環瓜氨酸肽檢測、抗核抗體檢測、可提取核抗原譜以及疾病特異性自身抗體抗體組合。為了提高診斷的準確性和病患監測的效率，多重免疫檢測、檢查室自動化、數位病理學、伴隨診斷生物標記策略以及與電子健康記錄的數據整合正日益影響市場應用趨勢。

診斷領域的變革性變化

自體免疫疾病的診斷正受到三大結構性變革的重塑：早期風險檢測、高通量檢測平台以及更專業的臨床決策支持。臨床醫生越來越需要能夠輔助鑑別診斷、監測疾病活動、預測復發、評估器官侵犯以及分層治療的檢測方法，而不是僅依賴單一檢測進行確診。這一點尤其重要，因為許多自體免疫疾病的症狀存在重疊，需要對血清學檢測、發炎標記、影像學檢查、切片檢查觀察以及病歷進行綜合解讀。

人工智慧（AI）的累積影響

人工智慧 (AI) 透過改善模式識別、工作流程優先排序和複雜資料集的解讀，進一步提升了自體免疫疾病診斷的價值。 AI 驅動的影像分析可以輔助對核抗體的螢光模式進行分類，而機器學習模型可以整合血清學、發炎標記、基因組學、藥物、症狀、影像學、病理學觀察和縱向臨床數據，從而識別需要轉診至專科醫生或進行密切監測的患者。

主要區域洞察：亞太地區、北美地區、歐洲、拉丁美洲、中東和非洲

在亞太地區，中國、印度、日本、韓國和澳洲等國正透過擴大醫院網路、增加對私人診斷領域的投資以及廣泛採用自動化免疫檢測平台，加速推進自體免疫疾病的診斷。龐大的人口規模、慢性病意識的提高、醫療旅遊的興起以及專科醫生診療管道的改善，都促進了檢測的使用。然而，保險報銷差異、都市區醫療資源取得不均以及免疫學專科服務分佈不均等問題，仍是限制自體免疫疾病診斷發展的重要阻礙因素。

關鍵區域洞察：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

東協市場，尤其是新加坡、泰國、馬來西亞、印尼、越南和菲律賓，其特點是私立醫院集團的擴張、醫療旅遊的蓬勃發展以及集中式檢測實驗室使用率的提高。這催生了對高擴充性自體免疫學檢測、乳糜瀉檢測、甲狀腺自體抗體檢測和結締組織疾病檢測組合的需求。在海灣合作理事會（GCC）國家，政府主導的醫療現代化、對三級醫療機構的投資、大規模篩檢計劃以及對支持專科診療路徑的進口先進診斷平台的需求，都在推動著市場的發展。

主要自體免疫疾病診斷市場的關鍵國家特定洞察

美國在自體免疫疾病診斷領域處於領先地位，這得益於其高檢測利用率、先進的參考實驗室、FDA已通過核准的平台、與保險掛鉤的廣泛臨床路徑以及對多參數檢測組合的積極應用。加拿大受益於公共醫療保健、國家運營的集中式實驗室模式以及基於循證醫學的利用管理，而墨西哥的需求則由都市區私人診斷實驗室、不斷擴大的專科診所和跨境醫療保健活動支撐。巴西擁有拉丁美洲最大的商機，這得益於其龐大的人口、廣泛的專科醫療保健、公私合營的檢測網路以及對風濕病、甲狀腺疾病和消化器官系統自體免疫疾病檢測日益成長的需求。

為行業領導者提供的實用建議

產業領導者應優先考慮已通過臨床驗證的檢測組合，以應對類風濕性關節炎、紅斑性狼瘡、乳糜瀉、自體免疫甲狀腺疾病、發炎性腸道疾病、第1型糖尿病、抗磷脂症候群和自體免疫肝病等高負擔疾病。組合策略應將成熟的血清學檢測與多重檢驗、分子檢測和數位化診斷功能結合，從而提高診斷特異性，支持複檢，並減少不必要的重複檢測。

調查方法

本執行摘要採用二手資料檢驗，利用公開且可驗證的資訊來源，包括監管指南、同行評審的調查方法資訊來源、專業學會建議、政府衛生數據、疾病負擔研究、報銷框架、檢查室認證標準和公共衛生報告。研究結果從多個角度檢驗，包括臨床應用、檢查室基礎設施、監管要求、技術成熟度、與指南的相關性以及區域可及性。

結論

隨著醫療系統致力於更早發現疾病、更準確地進行鑑別診斷並改善疾病監測，自體免疫疾病的診斷正變得更加精準、自動化和數據整合。雖然傳統的血清學檢測仍然至關重要，但鑑別診斷的格局正在轉向檢驗的多重檢測、人工智慧輔助的決策、完善的品管系統、標準化的報告以及循證臨床效用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：自體免疫疾病診斷市場：依產品分類

  • 檢測試劑盒和試劑
  • 裝置
    • 免疫檢測裝置
    • 微孔盤讀數儀

第8章：自體免疫疾病診斷市場：依檢測類型分類

  • 自體抗體和免疫學檢測
    • 抗核抗體
    • 環瓜氨酸化胜肽抗體
    • 疾病特異性自體抗體
  • 基因檢測
    • 染色體檢測
    • 分子檢測
  • 影像檢查
    • 磁振造影
    • 正子斷層掃描
    • 超音波檢查
  • 發炎標記物
    • C反應蛋白
    • 紅血球沉積速率

第9章：自體免疫疾病診斷市場：依技術分類

  • 酵素免疫分析法
  • 流式細胞技術
  • 螢光
  • 多重偵測
  • 次世代定序
  • 蛋白質印跡法

第10章：自體免疫疾病診斷市場：依樣本類型分類

  • 血
  • 唾液
  • 尿

第11章：自體免疫疾病診斷市場：依適應症分類

  • 器官特異性自體免疫疾病的診斷
    • 葛瑞夫茲氏病
    • 橋本氏甲狀腺炎
    • 多發性硬化症
    • 1型糖尿病
  • 系統性自體免疫疾病的診斷
    • 類風濕性關節炎
    • 全身性紅斑性狼瘡
    • 系統性硬皮症

第12章：自體免疫疾病診斷市場：依最終用戶分類

  • 門診部
  • 診斷檢查室
  • 醫院和診所
  • 研究機構

第13章：自體免疫疾病診斷市場：依通路分類

  • 線下銷售
  • 線上銷售

第14章：自體免疫疾病診斷市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章：自體免疫疾病診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：自體免疫疾病診斷市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • Abbott Laboratories
  • AbbVie Inc.
  • AESKU.GROUP GmbH & Co. KG
  • Autobio Diagnostics Co., Ltd.
  • Beckman Coulter, Inc. by Danaher Corporation
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioAgilytix Labs, LLC
  • bioMerieux SA
  • BIOSYSTEMS SA
  • Boditech Med Inc.
  • Chengdu Maccura Biotechnology Co., Ltd.
  • DiaSorin SpA
  • Exagen Inc.
  • F. Hoffmann-La Roche Ltd.
  • FUJIREBIO by HU Group company
  • GlaxoSmithKline plc
  • Grifols, SA
  • Hemagen Diagnostics, Inc.
  • JSR Life Sciences, LLC
  • Labcorp Holdings Inc.
  • Medical & Biological Laboratories Co. Ltd
  • Medsource Ozone Biomedicals Pvt. Ltd.
  • Menarini Group
  • Merck KGaA
  • Progentec Diagnostics, Inc.
  • PROTIA. iNC.
  • Quest Diagnostics, Inc.
  • Revvity, Inc.
  • RSR Limited
  • SD Biosensor, INC.
  • Sebia SA
  • Shanghai Kehua Bio-Engineering Co., Ltd.
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Shenzhen YHLO Biotech Co.,Ltd.
  • Siemens Healthineers AG
  • Svar Life Science AB
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech PLC
  • Werfen Group
Product Code: MRR-436901065F36

The Autoimmune Disease Diagnostics Market is projected to grow by USD 10.30 billion at a CAGR of 7.45% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.23 billion
Estimated Year [2026] USD 6.68 billion
Forecast Year [2032] USD 10.30 billion
CAGR (%) 7.45%

Autoimmune disease diagnostics are moving from episodic, symptom-led testing to earlier, multi-marker, and longitudinal assessment across rheumatology, gastroenterology, endocrinology, neurology, nephrology, and dermatology. Demand is supported by the high clinical burden of autoimmune disorders, delayed diagnosis in conditions such as systemic lupus erythematosus, rheumatoid arthritis, autoimmune thyroid disease, type 1 diabetes, inflammatory bowel disease, and celiac disease, and the need to distinguish inflammatory, infectious, malignant, and genetic mimics.

The market is anchored by established technologies such as indirect immunofluorescence assays, ELISA, chemiluminescent immunoassays, complement testing, HLA typing, tissue transglutaminase testing, anti-cyclic citrullinated peptide testing, antinuclear antibody testing, extractable nuclear antigen panels, and disease-specific autoantibody panels. Adoption is increasingly shaped by multiplex immunoassays, laboratory automation, digital pathology, companion-style biomarker strategies, and data integration with electronic health records to improve diagnostic confidence and patient monitoring.

Transformative Shifts in the Diagnostic Landscape

The autoimmune disease diagnostics landscape is being reshaped by three structural shifts: earlier risk detection, higher-throughput laboratory platforms, and more specialized clinical decision support. Clinicians increasingly require tests that support differential diagnosis, disease activity monitoring, flare prediction, organ involvement assessment, and treatment stratification rather than single-point confirmation. This is especially relevant because many autoimmune diseases have overlapping symptoms and may require combined interpretation of serology, inflammatory markers, imaging, biopsy findings, and clinical history.

Regulatory and quality expectations are also changing. The European Union In Vitro Diagnostic Regulation has raised requirements for clinical evidence, post-market surveillance, performance documentation, and notified body review, while U.S. laboratories continue to navigate evolving oversight of laboratory-developed tests. These shifts favor manufacturers and laboratories with validated assays, traceable controls, harmonized reporting, scalable automation, and strong medical education programs that help reduce false positives, false negatives, and unnecessary downstream testing.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding the value of autoimmune diagnostics by improving pattern recognition, workflow triage, and interpretation across complex datasets. AI-enabled image analysis can support antinuclear antibody immunofluorescence pattern classification, while machine learning models can integrate serology, inflammatory markers, genomics, medications, symptoms, imaging, pathology, and longitudinal clinical data to identify patients needing specialist referral or closer monitoring.

The cumulative impact is operational as well as clinical. AI can help laboratories reduce manual review burden, flag inconsistent results, prioritize high-risk samples, support reflex testing pathways, and strengthen quality management. Its strongest near-term value is expected in decision support and laboratory efficiency, provided models are clinically validated, bias-tested, explainable, cybersecurity-protected, and integrated into regulated diagnostic workflows with clinician oversight.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

In Asia-Pacific, autoimmune disease diagnostics benefit from expanding hospital networks, rising private diagnostics investment, and broad adoption of automated immunoassay platforms in China, India, Japan, South Korea, and Australia. Population scale, growing chronic disease awareness, medical tourism, and increasing specialist access support test utilization, although reimbursement variability, urban-rural access gaps, and uneven availability of subspecialty immunology services remain important constraints.

North America remains a high-value region because of advanced clinical laboratories, strong rheumatology and gastroenterology networks, broad use of molecular and multiplex testing, and active adoption of digital health and electronic health record integration. Europe is shaped by strong public health systems, CE-IVD requirements, clinical guideline adherence, and high standards for assay validation under the In Vitro Diagnostic Regulation. Latin America shows rising demand in Brazil and Mexico, supported by private laboratory chains, urban specialty care expansion, and growing awareness of autoimmune thyroid disease, rheumatoid arthritis, and celiac disease. The Middle East, particularly Gulf health systems, is investing in advanced hospital diagnostics, reference laboratories, and tertiary care infrastructure, while Africa's development is tied to reference laboratory capacity, infectious disease differential diagnosis, workforce training, and improved access to specialist testing in major urban centers.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN markets are characterized by growing private hospital groups, expanding medical tourism, and increasing use of centralized reference laboratories, especially in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. This creates demand for scalable autoimmune serology, celiac disease testing, thyroid autoantibody testing, and connective tissue disease panels. The GCC benefits from government-backed healthcare modernization, tertiary hospital investment, population screening initiatives, and demand for imported advanced diagnostic platforms that support specialist care pathways.

The European Union is a critical regulatory and commercialization benchmark because IVDR compliance affects assay classification, clinical evidence, post-market surveillance, and market access timelines. BRICS countries create large-volume opportunities, led by China, India, and Brazil, but require pricing discipline, localization, reimbursement awareness, and strong distributor or laboratory partnerships. G7 markets lead in specialty diagnostics adoption, reimbursement sophistication, digital laboratory infrastructure, and clinical research, while NATO countries collectively support resilient supply chains, laboratory interoperability, cybersecurity readiness, and healthcare security priorities relevant to uninterrupted essential diagnostic testing.

Key Country Insights Across Major Autoimmune Diagnostics Markets

The United States leads in autoimmune disease diagnostics through high test utilization, advanced reference laboratories, FDA-cleared platforms, broad insurance-linked clinical pathways, and strong adoption of multiplex panels. Canada benefits from publicly funded care, centralized provincial laboratory models, and evidence-based utilization management, while Mexico's demand is supported by urban private diagnostics, expanding specialty clinics, and cross-border healthcare activity. Brazil is the leading Latin American opportunity due to its large population, specialty care presence, public-private laboratory networks, and rising demand for rheumatology, thyroid, and gastrointestinal autoimmune testing.

In Europe, the United Kingdom emphasizes National Health Service pathways, clinical governance, and evidence-based testing; Germany combines advanced laboratory infrastructure with strong reimbursement discipline and high automation; France, Italy, and Spain show steady demand for rheumatoid arthritis, celiac disease, autoimmune thyroid disease, systemic autoimmune rheumatic disease, and inflammatory bowel disease diagnostics; and Russia relies on major urban centers for advanced immunology testing and specialist referral. In Asia-Pacific, China and India offer scale and fast laboratory modernization supported by hospital expansion and private diagnostics growth, Japan and South Korea emphasize quality, automation, precision medicine, and standardized workflows, and Australia benefits from guideline-driven testing, robust specialist referral systems, and strong laboratory accreditation practices.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated assay portfolios that address high-burden conditions such as rheumatoid arthritis, lupus, celiac disease, autoimmune thyroid disease, inflammatory bowel disease, type 1 diabetes, antiphospholipid syndrome, and autoimmune liver disease. Portfolio strategy should combine established serology with multiplex, molecular, and digital interpretation capabilities that improve diagnostic specificity, support reflex testing, and reduce unnecessary repeat testing.

Companies should invest in evidence generation, health economics, laboratory workflow automation, payer-facing clinical utility data, and education for clinicians and laboratory professionals. Regional success will depend on IVDR readiness, U.S. regulatory preparedness, local reference ranges, quality-controlled distribution, reagent supply resilience, interoperability with laboratory information systems, and partnerships with hospitals, reference laboratories, academic centers, and digital health platforms.

Research Methodology

This executive summary applies a secondary research methodology using publicly available, verifiable sources, including regulatory guidance, peer-reviewed clinical literature, professional society recommendations, government health data, disease burden studies, reimbursement frameworks, laboratory accreditation standards, and public health reports. Insights are triangulated across clinical adoption, laboratory infrastructure, regulatory requirements, technology maturity, guideline relevance, and regional access patterns.

Market interpretation is based on evidence-linked indicators rather than unverified assumptions. Key inputs include diagnostic guideline relevance, assay validation requirements, automation adoption, patient access dynamics, specialist density, reimbursement environment, laboratory quality systems, and the role of reference laboratories in scaling autoimmune disease testing. No market sizing, market share, or forecasting assumptions are used in this analysis.

Conclusion

Autoimmune disease diagnostics are becoming more precise, automated, and data-integrated as healthcare systems seek earlier detection, better differential diagnosis, and improved disease monitoring. Established serology remains essential, but differentiation is shifting toward validated multiplex panels, AI-enabled interpretation, robust quality systems, standardized reporting, and evidence-based clinical utility.

Organizations that align innovation with regulatory compliance, affordability, laboratory efficiency, supply reliability, and physician confidence will be best positioned to advance clinical adoption. The strongest opportunities lie in markets where specialist access, reimbursement support, laboratory accreditation, and diagnostic infrastructure converge to support timely autoimmune disease diagnosis and long-term patient management.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Autoimmune Disease Diagnostics Market, by Product

  • 7.1. Assay Kits & Reagents
  • 7.2. Instruments
    • 7.2.1. Immunoassay Analyzers
    • 7.2.2. Microplate Readers

8. Autoimmune Disease Diagnostics Market, by Test Type

  • 8.1. Autoantibodies & Immunologic Test
    • 8.1.1. Antinuclear Antibodies
    • 8.1.2. Cyclic Citrullinated Peptide Antibodies
    • 8.1.3. Disease-Specific Autoantibodies
  • 8.2. Genetic Testing
    • 8.2.1. Chromosomal Tests
    • 8.2.2. Molecular Tests
  • 8.3. Imaging Tests
    • 8.3.1. Magnetic Resonance Imaging
    • 8.3.2. Positron Emission Tomography
    • 8.3.3. Ultrasound
  • 8.4. Inflammatory Markers
    • 8.4.1. C-reactive protein
    • 8.4.2. Erythrocyte Sedimentation Rate

9. Autoimmune Disease Diagnostics Market, by Technology

  • 9.1. Enzyme-Linked Immunosorbent Assay
  • 9.2. Flow Cytometry
  • 9.3. Immunofluorescence Assay
  • 9.4. Multiplex Assays
  • 9.5. Next-Generation Sequencing
  • 9.6. Western Blotting

10. Autoimmune Disease Diagnostics Market, by Sample Type

  • 10.1. Blood
  • 10.2. Saliva
  • 10.3. Urine

11. Autoimmune Disease Diagnostics Market, by Indication

  • 11.1. Organ-Specific Autoimmune Disease Diagnostics
    • 11.1.1. Graves' Disease
    • 11.1.2. Hashimoto's Thyroiditis
    • 11.1.3. Multiple Sclerosis
    • 11.1.4. Type 1 Diabetes
  • 11.2. Systemic Autoimmune Disease Diagnostics
    • 11.2.1. Rheumatoid Arthritis
    • 11.2.2. Systemic Lupus Erythematosus
    • 11.2.3. Systemic Sclerosis

12. Autoimmune Disease Diagnostics Market, by End User

  • 12.1. Ambulatory Care Centers
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals & Clinics
  • 12.4. Research Institutions

13. Autoimmune Disease Diagnostics Market, by Distribution Channel

  • 13.1. Offline Sales
  • 13.2. Online Sales

14. Autoimmune Disease Diagnostics Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Autoimmune Disease Diagnostics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Autoimmune Disease Diagnostics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Abbott Laboratories
  • 18.2. AbbVie Inc.
  • 18.3. AESKU.GROUP GmbH & Co. KG
  • 18.4. Autobio Diagnostics Co., Ltd.
  • 18.5. Beckman Coulter, Inc. by Danaher Corporation
  • 18.6. Becton, Dickinson and Company
  • 18.7. Bio-Rad Laboratories, Inc.
  • 18.8. BioAgilytix Labs, LLC
  • 18.9. bioMerieux SA
  • 18.10. BIOSYSTEMS S.A.
  • 18.11. Boditech Med Inc.
  • 18.12. Chengdu Maccura Biotechnology Co., Ltd.
  • 18.13. DiaSorin S.p.A.
  • 18.14. Exagen Inc.
  • 18.15. F. Hoffmann-La Roche Ltd.
  • 18.16. FUJIREBIO by H.U. Group company
  • 18.17. GlaxoSmithKline plc
  • 18.18. Grifols, S.A
  • 18.19. Hemagen Diagnostics, Inc.
  • 18.20. JSR Life Sciences, LLC
  • 18.21. Labcorp Holdings Inc.
  • 18.22. Medical & Biological Laboratories Co. Ltd
  • 18.23. Medsource Ozone Biomedicals Pvt. Ltd.
  • 18.24. Menarini Group
  • 18.25. Merck KGaA
  • 18.26. Progentec Diagnostics, Inc.
  • 18.27. PROTIA. iNC.
  • 18.28. Quest Diagnostics, Inc.
  • 18.29. Revvity, Inc.
  • 18.30. RSR Limited
  • 18.31. SD Biosensor, INC.
  • 18.32. Sebia S.A.
  • 18.33. Shanghai Kehua Bio-Engineering Co., Ltd.
  • 18.34. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 18.35. Shenzhen YHLO Biotech Co.,Ltd.
  • 18.36. Siemens Healthineers AG
  • 18.37. Svar Life Science AB
  • 18.38. Takeda Pharmaceutical Company Limited
  • 18.39. Thermo Fisher Scientific Inc.
  • 18.40. Trinity Biotech PLC
  • 18.41. Werfen Group

LIST OF FIGURES

  • FIGURE 1. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ASSAY KITS & REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ASSAY KITS & REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ASSAY KITS & REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNOASSAY ANALYZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNOASSAY ANALYZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNOASSAY ANALYZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MICROPLATE READERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MICROPLATE READERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MICROPLATE READERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AUTOANTIBODIES & IMMUNOLOGIC TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AUTOANTIBODIES & IMMUNOLOGIC TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AUTOANTIBODIES & IMMUNOLOGIC TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTINUCLEAR ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTINUCLEAR ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTINUCLEAR ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CYCLIC CITRULLINATED PEPTIDE ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CYCLIC CITRULLINATED PEPTIDE ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CYCLIC CITRULLINATED PEPTIDE ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DISEASE-SPECIFIC AUTOANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DISEASE-SPECIFIC AUTOANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DISEASE-SPECIFIC AUTOANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENETIC TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENETIC TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHROMOSOMAL TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CHROMOSOMAL TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHROMOSOMAL TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MOLECULAR TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MOLECULAR TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MOLECULAR TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMAGING TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMAGING TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMAGING TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ULTRASOUND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ULTRASOUND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFLAMMATORY MARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INFLAMMATORY MARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFLAMMATORY MARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL C-REACTIVE PROTEIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL C-REACTIVE PROTEIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL C-REACTIVE PROTEIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ERYTHROCYTE SEDIMENTATION RATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ERYTHROCYTE SEDIMENTATION RATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ERYTHROCYTE SEDIMENTATION RATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IMMUNOFLUORESCENCE ASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IMMUNOFLUORESCENCE ASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMMUNOFLUORESCENCE ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MULTIPLEX ASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MULTIPLEX ASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MULTIPLEX ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL WESTERN BLOTTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL WESTERN BLOTTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL WESTERN BLOTTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SALIVA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SALIVA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SALIVA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GRAVES' DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GRAVES' DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GRAVES' DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HASHIMOTO'S THYROIDITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HASHIMOTO'S THYROIDITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HASHIMOTO'S THYROIDITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL SYSTEMIC SCLEROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL SYSTEMIC SCLEROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL SYSTEMIC SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL OFFLINE SALES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL OFFLINE SALES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL OFFLINE SALES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ONLINE SALES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ONLINE SALES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ONLINE SALES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 244. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 245. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2018-2032 (USD MILLION)
  • TABLE 247. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 248. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 249. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2018-2032 (USD MILLION)
  • TABLE 250. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 253. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 254. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 255. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. GCC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 288. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 289. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 290. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2018-2032 (USD MILLION)
  • TABLE 292. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 293. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 294. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2018-2032 (USD MILLION)
  • TABLE 295. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 296. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 298. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 299. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 300. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. G7 AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 302. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 303. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 304. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 305. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2018-2032 (USD MILLION)
  • TABLE 307. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 308. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 309. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2018-2032 (USD MILLION)
  • TABLE 310. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 311. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 313. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 314. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 315. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 316. NATO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 317. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-